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Background: Epicardial fat, quantified in a single multi-slice computed tomography (MSCT) slice, is a reliable
estimate of total epicardial fat volume (EFV). We sought to determine risk factors for EFV detected in a single-slice
MSCT measurement (ssEFV) in pre-dialysis chronic kidney disease (CKD) patients. Our primary objective was to
determine the association between ssEFV and coronary artery calcification (CAC).
Methods: 94 pre-dialysis stage 3–5 CKD patients underwent MSCT to measure ssEFV and CAC. ssEFV was quantified
at the level of the left main coronary artery. Measures of inflammation, traditional and kidney-related cardiovascular
disease risk factors were collected.
Results: Mean age: 63.7 ± 14 years, 56% male, 39% had diabetes, and mean eGFR: 25.1 ± 11.9 mL/min/1.73 m2.
Mean ssEFV was 5.03 ± 2.4 cm3. By univariate analysis, body mass index (BMI) (r = 0.53; P = <0.0001), abdominal
obesity (r = 0.51; P < 0.0001), high density lipoprotein (HDL) cholesterol (r = − 0.39; P = <0.0001), insulin resistance
(log homeostasis model assessment of insulin resistance (log HOMA-IR)) (r = 0.38, P = 0.001), log interleukin-6 (IL-6)
(r = 0.34; P = 0.001), and log urinary albumin to creatinine ratio (UACR) (r = 0.30, P = 0.004) demonstrated the
strongest associations with ssEFV. Log coronary artery calcification (log CAC score) (r = 0.28, P = 0.006), and log
fibroblast growth factor-23 (log FGF-23) (r = 0.23, P = 0.03) were also correlated with ssEFV. By linear regression, log
CAC score (beta =0.40; 95% confidence interval (CI), 0.01-0.80; P = 0.045), increasing levels of IL-6 (beta = 0.99;
95% CI, 0.38 – 1.61; P = 0.002), abdominal obesity (beta = 1.86; 95% CI, 0.94 - 2.8; P < 0.0001), lower HDL cholesterol
(beta = −2.30; 95% CI, – 3.68 to −0.83; P = 0.002) and albuminuria (log UACR, beta = 0.81; 95% CI, 0.2 to 1.4; P = 0.01)
were risk factors for increased ssEFV.
Conclusions: In stage 3–5 CKD, coronary calcification and IL-6 and were predictors of ssEFV. Further studies are
needed to clarify the mechanism by which epicardial fat may contribute to the pathogenesis of coronary disease,
particularly in the CKD population.
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The metabolic syndrome is a risk factor for type 2
diabetes mellitus [1] and cardiovascular disease (CVD)
[2], and is a risk factor for the development of incident
chronic kidney disease (CKD) [3,4]. This syndrome
emphasizes the role of visceral abdominal adipose tissue
in the pathogenesis of disease. Visceral adipose tissue is
highly metabolically active and produces hormones
and cytokines, including those with anti-atherosclerotic
properties (e.g. adiponectin [5]) and those with pro-
atherosclerotic properties (e.g. Interleukin-6 (IL-6) and
tumor necrosis factor α) [6]. In obesity, the balance
between such pro- and anti-atherogenic factors is dis-
turbed. As a result, pro-atherogenic and inflammatory
cytokine production increases [6], interferes with insulin
signalling, and contributes to the development of insulin
resistance and vascular wall inflammation [7,8].
Epicardial fat, a visceral deposit of adipose tissue located
between the myocardium and visceral pericardium, is also
metabolically active and produces many of the same pro-
atherogenic cytokines found in visceral abdominal fat
[9,10]. In the general population, epicardial adipose tissue
has been shown to correlate with coronary artery calcifica-
tion (CAC) [11] and the metabolic syndrome [12]. In
patients with end stage kidney disease requiring dialysis,
the total volume of epicardial fat is correlated with CAC
[13], and is significantly greater in dialysis patients versus
healthy controls [14]. CAC is an important manifestation
of cardiovascular disease in CKD patients. The burden of
CAC is more severe in CKD patients compared to the
general population [15], in part due to the combined im-
pact of traditional and kidney-related CVD risk factors in
contributing to CAC [16]. To our knowledge, epicardial
fat has not been quantified in the pre-dialysis CKD popu-
lation nor its potential association with CAC or markers
of inflammation.
Measurement of the total volume of epicardial fat
requires radiological techniques that are time-consuming
and labor-intensive in clinical settings; however, Oyama
et al. determined the single-slice epicardial fat area
(ssEFA), measured at the level of the left main coronary
artery (LMCA), provides a reliable estimate of total epicar-
dial fat volume (EFV) [17]. In this study, we used a similar
technique as Oyama et al., and measured the single slice
epicardial fat volume (ssEFV) at the level of the LMCA in
a cohort of stage 3–5 CKD patients, in order to test the
hypothesis that coronary calcification is more severe in
CKD patients with greater epicardial fat. Therefore, our
primary objective was to determine the cross sectional as-
sociation between ssEFV and CAC, and our secondary
objectives were to determine the associations between
ssEFV and kidney function, traditional and kidney-related
CVD risk factors, including markers of inflammation,
obesity and insulin resistance.Methods
In 2005, 174 pre-dialysis CKD patients were enrolled in a
study of CAC in CKD [18]. The full methods are described
elsewhere, but patients were eligible to participate if they
were greater than 18 years of age and had stage 3–5 CKD
(not requiring dialysis and excluding acute kidney injury).
All patients who had CAC scores measured in 2005 were
invited to undergo repeat multi-slice CT (MSCT) scan for
quantification of CAC in 2009, and had repeat clinical and
biochemical assessments performed. In 2011, patients
were included if they had both a CAC score result and a
ssEFV result. Of the original 174 patients, 17 patients died,
31 patients progressed to dialysis, 5 were transplanted, 7
were discharged to the care of their family physician, 2
had moved, and 5 were lost to follow-up or refused
consent. This left 107 patients of which 95 agreed to par-
ticipate. Of these, one CAC score was not interpretable
because the LMCA could not be identified due to motion
artefact, leaving 94 patients who had data for both CAC
and ssEFV. All patients gave informed consent, and the
study protocol was approved by the Queen’s University
Health Sciences and Affiliated Teaching Hospitals Re-
search Ethics Board.
National Kidney Foundation criteria were applied to
diagnose CKD [19]. Diagnoses of hypertension were docu-
mented as per 2006 Canadian Hypertension Education
Program Guidelines [20], and diabetes mellitus as per the
Canadian Diabetes Association criteria [21]. Metabolic
syndrome was defined as fulfilling at least 3 of 5 criteria
from the National Cholesterol Education Program Adult
Treatment Panel III 2005 criteria [22].
Laboratory measures
Fasting serum laboratory measured in 2009 at Kingston
General Hospital’s Core Laboratory included creatinine
(Jaffe rate method, Beckman Coulter UniCel DxC 800
SYNCHRON Clinical System assay, traceable to isotope
dilution mass spectroscopy), glucose, phosphorus, total
calcium, intact parathyroid hormone (iPTH),(chemilu-
minescent immunoassay, Beckman Coulter UniCel DxI
800 Access Immunoassay System, Beckman Coulter Inc.,
Fullerton CA), albumin, high-sensitivity C-reactive pro-
tein (hsCRP),(Beckman Coulter UniCel DxC 600/800
SYNCHRON Clinical System, Beckman Coulter Inc.,
Fullerton CA), total cholesterol, low density lipoprotein
cholesterol (LDL), high density lipoprotein cholesterol
(HDL), and triglycerides.
Blood samples were stored at –80°C, and after a single
freeze-thaw cycle the following were measured from
plasma in duplicate at the Ontario Cancer Biomarker
Network, Toronto, ON, Canada: 1,25-Dihydroxyvitamin D,
enzymeimmunoassay (Immunodiagnostic Systems Inc.,
Fountain Hills, Arizona), 25-hydroxyvitamin D, enzymeim-
munoassay (Immunodiagnostic Systems Inc., Fountain
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assay (ELISA) (ALPCO Diagnostics, Salem, NH), insulin
(single measure) Human Serum Adipokine (Panel B) Kit
Protocol Immunoassay, (Milliplex Analytes, Millipore Corp,
St. Charles, MI), and serum FGF-23 ELISA, (measured in
duplicate), (ALPCO Diagnostics, Salem, NH). Plasma IL-6
was measured in duplicate at Queen’s University using
ELISA (R&D Systems, Minneapolis, MN).
The 4-variable MDRD Study equation [23], re-expressed
for standardized creatinine [24], was used to estimate eGFR.
Albuminuria was detected by the urinary albumin-to-
creatinine ratio (UACR mg/mmol). Weight and height data
were collected on each individual to calculate body mass
index (BMI) in kg/m2. Abdominal obesity was defined as a
waist circumference of >88 cm in women and >102 cm
in men [22]. Insulin resistance was assessed using the fo-
llowing validated formula: homeostasis model assessment of
insulin resistance (HOMA-IR) = (fasting glucose [mmol/1] ×
fasting insulin [μU/ml])/22.5 [25]. Because of confounding
introduced by exogenous insulin administration to
HOMA-IR results, HOMA-IR was only measured in
patientswhowerenottreatedwithinsulin(N = 72).
Coronary artery calcification measurement
CAC scores were evaluated using the General Electric (GE)
VCT 64 slice helical CT scanner, (Waukesha, Wisconsin,
USA) and data was processed by Smartscore software, ver-
sion 3.5 from GE Medical Systems (Waukesha, Wisconsin,
USA). The GE VCT 64 slice helical CT scanner scans and
reconstructs 8 slices simultaneously, using a step and shoot
technique. Each slice is 2.5 mm in thickness with no over-
lap. Images were acquired with prospective gating tech-
nique using a discrete algorithm [26]. The total CAC score
was generated as per the Agatston method and reported in
Agatston units (AU) [27].
Single slice epicardial Fat volume measurement
The 2009 MSCT scans were re-analyzed in 2011 for de-
termination of ssEFV. Oyama et al. [17] described a
method of estimating the total EFV by MSCT scan,
using a single MSCT slice located at the level of the
LMCA. Single slice epicardial fat area (ssEFA) measured
at the level of the LMCA correlated well with total EFV
in this study (r = 0.92; P < 0.0001) [17]. We used a simi-
lar method as Oyama et al. The EFV of two MSCT slices
nearest the origin of the LMCA were measured on each
patient (GE Advantage Workstation, “volume tool”).
Pixels in the pericardium with a density from −30 to −230
Hounsfield units were considered fat (Figure 1). The aver-
age of these two single slice epicardial fat volumes at the
LMCA determined the ssEFV and was recorded in centi-
metres cubed. The single slice epicaridal fat area at the
level of the LMCA was also measured by dividing the
ssEFV by the MSCT slice thickness (2.5 mm) andrecorded in centimetres squared. A random sample of 13
patients (5 patients with ssEFV 0–5 cm3; 4 patients with
ssEFV 5–10 cm3, and 4 patients with ssEFV > 10 cm3) was
chosen to verify the agreement between the two MSCT
ssEFV measures. The intra-class correlation was at 0.99;
95% CI 0.96 to 1.0; P < 0.0001).
Statistical methods
Summary statistics are expressed as means and standard
deviations, medians and inter-quartile ranges (IQR), or
percentages, as appropriate. Bivariate analysis was per-
formed to evaluate the associations between ssEFV and a
priori chosen risk factors, including CAC, BMI, abdominal
obesity, HOMA-IR, hsCRP, IL-6, age, sex, hypertension,
HDL cholesterol, LDL cholesterol, total cholesterol, trigly-
cerides, diabetes mellitus, smoking status and other kidney
related CVD risk factors (albuminuria (UACR), fetuin,
osteoprotegerin, FGF-23, iPTH, 25- hydroxyvitamin D, and
1,25-Dihydroxyvitamin D levels. Prior to analysis, CAC,
hsCRP, IL-6 and HOMA-IR were logarithmically trans-
formed to ensure normality for parametric testing.
A series of multivariable linear regression models were
constructed to identify risk factors for increased ssEFV.
All variables from the bivariate analysis which showed an
association with ssEFV at the significance level P < 0.10
were included in the initial multivariable linear regression
models. All statistical analyses were performed using IBM
SPSS Statistics 19.0.
Results
Table 1 describes baseline clinical characteristics of the 94
included study participants. The prevalence of hyperten-
sion and diabetes were high, 32% of patients had stage 3
CKD, 47% stage 4 CKD, 19% stage 5 CKD, and 42% had
evidence of macro-albuminuria (UACR > 30 mg/mmol).
In general, patients did not have hyperphosphatemia but
vitamin D levels were low and FGF-23 levels were ele-
vated. 79% of patients had CAC scores greater than 10 AU
(minimal CAC), and 38% having CAC scores greater than
400 AU (severe CAC).
The average ssEFV measured at the level of LMCA was
5.03 ± 2.44 cm3; the corresponding average ssEFA was
20.1 ± 9.77 cm2. ssEFV was significantly higher is patients
with metabolic syndrome versus those without metabolic
syndrome (ssEFV 5.45 cm3 ± 2.3 cm3 versus 2.84 cm3 ±
1.9 cm3; P <0.0001), in patients with diabetes mellitus
versus those without a diagnosis of diabetes, (ssEFV
5.74 cm3 ± 2.14 cm3 versus 4.52 cm3 ± 2.5 cm3; P = 0.02)
and in patients who had increasing levels of insulin resis-
tance. Patients with HOMA-IR values greater than the
median had significantly higher ssEFV versus patients
whose HOMA-IR values were less than the median
(ssEFV 6.26 cm3; IQR 3.99 to 7.47 cm3 versus 3.39 cm3;







Figure 1 Axial MSCT scan at the left of the left main coronary artery demonstrating relevant landmarks for the measurement of single
slice epicardial fat volume (ssEFV) in a 72 year old female chronic kidney disease patient.
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ing associations of ssEFV, and a priori chosen risk factors.
BMI, abdominal obesity, HDL cholesterol, triglycerides,
insulin resistance (log HOMA-IR), markers of inflamma-
tion (log IL-6, log hsCRP, hypoalbuminemia and albumi-
nuira) and log CAC score demonstrated the strongest
associations with ssEFV. In terms of other kidney related
CVD risk factors, log FGF-23 correlated with ssEFV
(r = 0.23; P = 0.03); however, kidney function (eGFR) was
not associated with ssEFV, missing statistical significance,
nor was 25-hydroyxvitamin D, 1,25-Dihydroxy vitamin D,
fetuin, osteoprotegerin or serum phosphorus.
A series of multivariable linear regression models
(Tables 3 and 4) were developed to determine risk factors
for ssEFV, adjusted for level of kidney function and dia-
betes mellitus. Coronary artery calcification, increasing
levels of IL-6, abdominal obesity, lower HDL cholesterol,
and albuminuria were significantly associated with greater
ssEFV. In a separate multivariable regression model
including metabolic syndrome as a co-variate (rather than
the individual metabolic syndrome components), an asso-
ciation between metabolic syndrome and ssEFV was
observed (metabolic syndrome ß = 1.8; 95% confidence
interval 0.41 to 3.2; P = 0.01)(full model not shown). This
association no longer remained robust once adjusted for
body mass index (ß = 1.2; 95% confidence interval −0.07–
2.45; P = 0.06) (Table 4). Considering insulin resistance, al-
though HOMA-IR was correlated with ssEFV, thisassociation no longer remained in the multivariable
regression model (N = 72; HOMA-IR ß =1.3 ; 95% confi-
dence interval −0.47 – 3.1; P = 0.15) (full model not shown).
Discussion
Risk factors for epicardial fat have not been previously
assessed in pre-dialysis CKD patients, who are recognized
to have a markedly increased risk of CVD and adverse car-
diovascular events, compared to individuals from the gen-
eral population [28]. Our results demonstrate the following
findings:
1. The burden of epicardial fat volume is greater in
individuals with metabolic syndrome, increased
insulin resistance or diabetes mellitus.
2. By univariate analysis, epicaridal fat volume is
correlated with coronary artery calcification, body
mass index, dyslipidemia, insulin resistance
(HOMA-IR), abdominal obesity, albuminuria and
interleukin-6. FGF-23, a biomarker indicating
disrupted phosphorus homeostasis, was also
correlated with EFV.
3. In the multivariable adjusted regression models,
the association between epicardial fat volume and
coronary artery calcification remains robust. This
observation, while not causal, suggests epicardial
fat deposition may be important in the etiology
of CAC.
Table 1 Baseline clinical characteristics of study




Age (years) 63.7 14
Male sex 56%
Body mass index (kg/m2) 31.7 9.3
eGFR (ml/min/1.73 m2) 25.1 11.9
UACR (mg/mmol) (N = 88) 22.2 4-118
Hypertension (N = 93) 94.7%
Systolic Blood Pressure (mmHg)
(N = 93)
131.8 17.4





HOMA-IR (uU/mL) (N = 72) 2.19 1.19–3.94
Glucose (mmol/l) 5.7 5.2–6.7
Hemoglobin A1C% (N = 93) 6.1 5.6–7.2
Calcium (mmol/l) 2.30 .022
Phosphorus (mmol/l) 1.29 0.27
Albumin (g/l) 37.3 3.6
Total cholesterol (mmol/l) (N = 93) 4.15 1.29
HDL cholesterol (mmol/l) (N = 93) 1.01 0.34
LDL cholesterol (mmol/l) (N = 92) 2.37 1.05
Triglycerides (mmol/l) (N = 93) 1.8 1.06
hsCRP (mg/l) (N = 93) 3.00 1.25–6.1
25-Hydroxy Vitamin D (nmol/l) 54.67 44.9–69.1
1,25-Dihydroxyvitamin D (pmol/l) 49.6 30.8–71.5
FGF-23 (RU/ml) 150.8 73.4–305.3
Fetuin (g/L) (N = 93) 0.613 0.13
Osteoprotegerin (pmol/L) 4.09 1.86




ssEFV (cm3) 5.03 2.4
ssEFA (cm2) 20.1 9.77
eGFR = estimated glomerular filtration rate; UACR = urinary albumin to
creatinine ratio; HOMA-IR = homeostasis model assessment of insulin
resistance; HDL = high density lipoprotein; LDL = low density lipoprotein;
hsCRP = high sensitivity C-reactive protein; FGF-23 = fibroblast growth factor
−23; AU = Agatston units; ssEFV = single slice epicardial fat volume at the level
of the left main coronary artery (LMCA); ssEFA = single slice epicardial fat area
at the level of the LMCA; SD = standard deviation; IQR = interquartile range.
Table 2 Correlations with epicardial fat volume (N = 94)
Variable r P
Age 0.06 0.60
Body Mass Index 0.53 <0.0001
eGFR −0.18 0.09
log UACR (N = 88) 0.30 0.004
Systolic Blood Pressure (N = 93) 0.07 0.50
Diastolic Blood Pressure (N = 93) −0.06 0.60
log Coronary artery calcification score 0.28 0.006
Abdominal obesity 0.51 <0.0001
Log HOMA-IR (N = 72) 0.38 0.001
Fasting glucose 0.23 0.02
Triglycerides (N = 93) 0.34 0.001
LDL cholesterol (N = 92) −0.17 0.11
HDL cholesterol (N = 93) −0.39 <0.0001
Log hsCRP (N = 93) 0.30 0.003
Log Interleukin - 6 0.34 0.001
Log FGF-23 0.23 0.03
Phosphorus 0.08 0.50
Albumin −0.28 0.007
25-Hydroxy Vitamin D −0.14 0.17
1,25-Dihydroxyvitamin D −0.13 0.23
Fetuin-A (N = 93) −0.13 0.20
Osteoprotegerin 0.03 0.80
eGFR = estimated glomerular filtration rate; UACR = urinary albumin to
creatinine ratio; HOMA-IR = homeostasis model assessment of insulin
resistance; HDL = high density lipoprotein; LDL = low density lipoprotein;
hsCRP = high sensitivity C-reactive protein.
FGF-23 = fibroblast growth factor −23.
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the literature; however, measures of EFV in pre-dialysis
CKD patients are not available. We employed a similar
technique as Oyama et al. [17] to quantify EFV, which
involved measuring the ssEFV and ssEFA at the level of
the LMCA. While we recognize that differences in pa-
tient populations limit comparisons across studies, the
average ssEFA in the pre-dialysis CKD cohort from this
study population (BMI 31.7 ± 9.3 kg/m2, 39% diabetes,95% hypertension), appears to be substantially greater
(20.1 ± 9.77 cm2) than results obtained in the Oyama
study (4.4 ± 2.2 cm2) of 72 Japanese men from the gen-
eral population (BMI 23.4 ± 3.0 kg/m2, 38% diabetes,
60% hypertension) [17].
Our data demonstrate ssEFV was greater in CKD patients
with metabolic syndrome, insulin resistance, or diabetes.
Although metabolic syndrome and insulin resistance were
correlated with ssEFV in univarate analyses, these associa-
tions did not remain in the multivariable regression models,
with metabolic syndrome just missing statistical signifi-
cance (Table 4). However, the multivariable regression
model including the individual components of metabolic
syndrome as covariates demonstrated abdominal obesity
and low HDL cholesterol to be predictors of ssEFV
(Table 3). Yerramasu et al. have reported similar findings in
333 diabetic (non CKD) patients, where the association be-
tween metabolic syndrome and EFV no longer remained
significant in the multivariable adjusted regression model
once adjusted for body mass index [11].
Epicardial adipose tissue is emerging as a novel risk
factor for CVD development [29] and progression [11].
It is hypothesized that the proximity of epicardial fat to
Table 3 Multivariable regression risk factors for single
slice epicardial fat volume (N = 94), R2 = 0.49





Abdominal obesity 1.86 (0.94–2.80) <0.0001
Log UACR 0.81 (0.20–1.40) 0.01
HDL cholesterol −2.30 (−3.68–-0.83) 0.002
Interleukin −6 0.99 (0.38–1.61) 0.002
Diabetes mellitus −0.86 (−1.8–0.10) 0.08
eGFR (per 10 ml/min/
1.73 m2 decrease)
0.25 (−0.15–0.65) 0.21
UACR = urinary albumin-to-creatinine ratio; HDL = high density lipoprotein;
eGFR = estimated glomerular filtration rate.
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lation, allows pro-atherogenic hormones and cytokines
released from epicardial adipose tissue to act locally in a
paracrine or vasocrine manner to promote coronary dis-
ease [10,30]. We evaluated the association between mar-
kers of inflammation (IL-6, hsCRP, hypoalbuminemia and
albuminuria) and ssEFV in this pre-dialysis CKD cohort.
Of these, the associations between IL-6 (Tables 3 and 4)
and albuminuria (log UACR, Table 3) and ssEFV remained
robust in the multivariable adjusted models. In dialysis
patients, Turkmen et al. also reported that epicardial fat
correlated with the MIAC syndrome (malnutrition, in-
flammation (assessed by hsCRP), atherosclerosis/ calcifica-
tion)), and that the burden of epicardial fat increased as
the number of MIAC components increased [14]. Albu-
minuria is an important risk factor predicting the likeli-
hood of progressive kidney function deterioration [31], is a
marker of endothelial dysfunction [32], is a risk factor for
CVD, and is associated with increased abdominal adipo-
sity [33]. Taken together, these data suggest a relationshipTable 4 Multivariable regression risk factors for single
slice epicardial fat volume (N = 94), R2 = 0.49
Model 2 Co-Variates EFV Beta co-efficient P
(95% Confidence Interval)
Log Coronary artery calcification
score
0.48 (0.06–0.88) 0.025
Log UACR 0.25 (−0.44–0.97) 0.48
Interleukin −6 0.73 (0.14–1.30) 0.02
Diabetes mellitus −0.47 (−1.38–0.45) 0.31
eGFR (per 10 ml/min/1.73 m2
decrease)
−0.05 (−0.45–0.35) 0.81
Body Mass Index (Kg/m2) .015 (.09–0.21) <.0001
Metabolic syndrome (yes/no) 1.2 (−0.07–2.45) .06
UACR = urinary albumin-to-creatinine ratio; eGFR = estimated glomerular
filtration rate.between inflammation, epicardial adipose tissue, and the
development of coronary disease, in CKD patients.
The mechanism regarding IL-6 and epicardial fat remains
uncertain; however, both circulating, and local IL-6 produc-
tion have been demonstrated as risk factors for epicardial
fat deposition in the general population. For example,
Yerramasu et al. showed that IL-6 levels were significantly
higher across increasing tertiles of epicardial adipose tissue
in asymptomatic diabetic patients [11]. Shibasaki et al.
compared IL-6 expression in the epicardial adipose tissue
of patients with CAD compared to those without CAD,
and showed that while IL-6 levels were increased when
sampled from epicardial fat, circulating levels of IL-6 did
not differ between the two groups [34].
To our knowledge, the association we report between IL-
6 and ssEFV has not been previously reported in pre-
dialysis CKD patients. Importantly, IL-6 has been shown to
be a risk factor for CKD development. A large prospective
study of 1500 patients demonstrated IL-6 was associated
with the development of incident CKD [35]. The associ-
ation we report between IL-6 and ssEFV remained when
adjusted for kidney function (eGFR) and albuminuria
(Table 4), suggesting a link between elevated circulating in-
flammatory markers in CKD and local inflammation in fat
surrounding the coronary arteries.
Since the coronary arteries and epicardial adipose tissue
share the same micro-circulation, we also sought to deter-
mine the associations between epicardial adipose tissue
and coronary calcification. CAC, a form of vascular calcifi-
cation described in approximately 70% of predialysis CKD
patients, is increased in CKD patients compared to age
and sex match individuals from the general population.
The mechanism of accelerated vascular calcification in
CKD reflects disequilibrium between CAC inhibitors
(eg fetuin A) and promoters (eg: abnormal bone and min-
eral metabolism). We have reported previously that ap-
proximately 70% of pre-dialysis CKD patients demonstrate
CAC, and that CAC is increased in patients with higher
BMI, suggesting a link between obesity and CAC [36].
In this study, ssEFV and CAC were associated, and this
finding remained robust in the multi-variable regression
Model 1 adjusted for abdominal obesity, albuminuria,
renal function, diabetes mellitus, HDL cholesterol, and IL-
6 (Table 3). These data suggest that in addition to promot-
ing local atherosclerosis, excess epicardial adipose tissue
may also contribute to the development of vascular calcifi-
cation in CKD patients.
We also evaluated the associations of ssEFV with kidney-
related CVD risk factors, including markers of abnormal
bone and mineral metabolism (phosphorus, iPTH, 25-
hydroxyvitamin D, 1,25-Dihydroxyvitamin D, and FGF-23).
Of the tested CKD bone and mineral metabolism para-
meters, only FGF-23 was associated with ssEVF (log FGF-
23 (r = 0.23; P = 0.03); however, this association no longer
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phosphaturic hormone secreted by osteocytes, is a bio-
marker indicating disrupted phosphorus homeostasis in
CKD patients [37]. FGF-23 facilitates the maintenance of
normal serum phosphorus levels by decreasing renal phos-
phorus re-absorption in the kidney proximal tubule, and
consequently FGF-23 levels are elevated early in the course
of CKD, and increase as kidney function declines [38].
To our knowledge, this is the first study to report an as-
sociation between FGF-23 and EFV. Data supporting a po-
tential link between FGF-23, atherosclerosis, and measures
of obesity are limited. A study of 128 hemodialysis patients
demonstrated FGF-23 to be correlated with carotid artery
intima media thickness [39], and another study in elderly
individuals with normal renal function, demonstrated FGF-
23 levels to be significantly higher in subjects with
increased BMI, waist circumference and total body fat mass
as measured by dual x-ray absorptiometry [40]. Our results
are consistent with these findings, and suggest a potential
signal between excess epicardial adipose tissue and dis-
rupted phosphorus homeostasis, but future studies are
needed to explore this hypothesis.
There are limitations to this study worth consideration.
First, we quantified the ssEFV at the level of the LMCA,
and as such, our results do not represent the total EFV.
Nevertheless, the single slice method correlates well with
total EFV reported in the study by Oyama et al., the
method is easy, to use and has been demonstrated to be
reproducible [17]. Second, our sample size of 94 indivi-
duals may have been underpowered to demonstrate asso-
ciations of EFV with other traditional and kidney-related
CVD risk factors. Third, the optimal measures of insulin
resistance are obtained by the euglycemic hyperinsuline-
mic clamp procedure; however, it was not possible to
perform clamp procedures in this study. We wished to
employ a tool for measuring insulin resistance which
could be easily applied to clinical settings, and thus the
use of HOMA-IR was the preferred method. In addition,
since HOMA-IR was measured in 72 versus 94 patients,
the lack of association between EFV and HOMA-IR may
reflect inadequate sample size. Finally, our reported asso-
ciations of ssEFV and measures of obesity, insulin resist-
ance and metabolic syndrome, may have occurred because
such measures are inter-related. Further studies will be
required to confirm these findings and whether the role of
epicardial fat in contributing to CVD differs in CKD
patients versus the general population.
Conclusions
The ultimate goal of understanding the pathogenesis of
CVD in CKD patients is to discover new methods of risk
stratification and interventions for prevention and treat-
ment. The proximity of epicardial fat to the coronary ar-
teries suggests a potentially novel biological mechanismfor accelerated coronary calcification in pre-dialysis CKD
patients. To date, no studies have assessed whether inter-
ventions to decrease epicardial fat improve cardiovascular,
renal or metabolic outcomes in CKD patients. Further
studies are needed to clarify the mechanism by which epi-
cardial fat may contribute to the pathogenesis of coronary
disease, particularly in the CKD population.
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